Hormone Therapy and Venous Thromboembolism Among Postmenopausal Women: Impact of the Route of Estrogen Administration and Progestogens: The ESTHER Study

@article{Canonico2007HormoneTA,
  title={Hormone Therapy and Venous Thromboembolism Among Postmenopausal Women: Impact of the Route of Estrogen Administration and Progestogens: The ESTHER Study},
  author={M. Canonico and E. Oger and G. Plu-Bureau and J. Conard and G. Meyer and H. Lévesque and N. Trillot and M. Barrellier and D. Wahl and J. Emmerich and P. Scarabin},
  journal={Circulation},
  year={2007},
  volume={115},
  pages={840-845}
}
Background— Oral estrogen therapy increases the risk of venous thromboembolism (VTE) in postmenopausal women. Transdermal estrogen may be safer. However, currently available data have limited the ability to investigate the wide variety of types of progestogen. Methods and Results— We performed a multicenter case–control study of VTE among postmenopausal women 45 to 70 years of age between 1999 and 2005 in France. We recruited 271 consecutive cases with a first documented episode of idiopathic… Expand
Postmenopausal Hormone Therapy and Risk of Idiopathic Venous Thromboembolism Results From the E 3 N Cohort Study
Objective—Oral estrogen therapy increases venous thromboembolism risk among postmenopausal women. Although recent data showed transdermal estrogens may be safe with respect to thrombotic risk, theExpand
Hormone replacement therapy and the risk of venous thromboembolism: a population‐based study
TLDR
Transdermal HRT and tibolone were not associated with an increased risk of venous thromboembolism in postmenopausal women and the risks with oral formulations were particularly elevated during the first year of use but disappeared 4 months after discontinuation. Expand
Risk of venous thromboembolism associated with local and systemic use of hormone therapy in peri- and postmenopausal women and in relation to type and route of administration
TLDR
The risk of venous thromboembolism (VTE) is higher in users of systemic combined estrogen–progestogen treatment than in Users of estrogen only, and the risk of VTE was lower for women who used local estrogen than among those using oral estrogen only. Expand
Hormone therapy and recurrence of venous thromboembolism among postmenopausal women
TLDR
Oral but not transdermal estrogens are associated with a higher risk of recurrent VTE among postmenopausal women, providing further epidemiological evidence that transder mal estrogens may be safe with respect to VTE risk. Expand
Postmenopausal Hormone Therapy and Risk of Idiopathic Venous Thromboembolism: Results From the E3N Cohort Study
TLDR
Oral estrogen therapy increases venous thromboembolism risk among postmenopausal women using hormone therapy and route of estrogen administration and concomitant progestogens type are 2 important determinants of thrombotic risk. Expand
Concurrent use of statins and hormone therapy and risk of venous thromboembolism in postmenopausal women: a population-based case-control study
TLDR
Statins could potentially attenuate the increased risk associated with HT combinations of oral estrogens and progestogens, and this observation needs further confirmation in other large cohorts. Expand
Progestogens and venous thromboembolism in menopausal women: an updated oral versus transdermal estrogen meta-analysis
  • P. Scarabin
  • Medicine
  • Climacteric : the journal of the International Menopause Society
  • 2018
TLDR
Clinical findings emphasize the safety advantage of transdermal estrogen combined with progesterone and support the current evidence-based recommendations on HT, especially in women at high VTE risk. Expand
Risk of venous thromboembolism events in postmenopausal women using oral versus non-oral hormone therapy: A systematic review and meta-analysis.
TLDR
VTE risk was increased in postmenopausal women with no previous thromboembolic events using oral HT, and further clinical trials are needed to sort out the impact of different types of progestin and different estrogen doses and administration routes on VTE risk. Expand
Postmenopausal Hormone Therapy and Risk of Stroke
TLDR
The findings suggest that transdermal estrogens might be the safest option for short-term hormone therapy use, and both route of estrogen administration and progestogens were important determinants of IS. Expand
Synergism between oral estrogen therapy and cytochrome P450 3A5*1 allele on the risk of venous thromboembolism among postmenopausal women.
TLDR
Women with CYP3A5*1 allele using oral estrogen can define a subgroup at high VTE risk, and additional data are needed to assess the relevance of this genetic biomarker in the medical management of menopause. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 50 REFERENCES
Prothrombotic Mutations, Hormone Therapy, and Venous Thromboembolism Among Postmenopausal Women: Impact of the Route of Estrogen Administration
TLDR
In contrast to oral estrogen, transdermal estrogen does not confer additional risk on women who carry a prothrombotic mutation, and the safety of transDermal estrogen has to be confirmed in randomized trials. Expand
Hormone replacement therapy with estradiol and risk of venous thromboembolism--a population-based case-control study.
TLDR
It is concluded that use of HRT containing estradiol was associated with a threefold increased risk of VTE, but this increased risk was restricted to the first year of use. Expand
Risk of venous thromboembolism in users of hormone replacement therapy
TLDR
Current HRT use is associated with risk of VTE and the increased risk may be concentrated in new users, which needs to be weighed against the probable benefits of long-term treatment. Expand
Indicators of lifetime endogenous estrogen exposure and risk of venous thromboembolism
TLDR
The results show that the longer exposure to endogenous estrogen is associated with an increased VTE risk. Expand
Prospective study of exogenous hormones and risk of pulmonary embolism in women
TLDR
The risk of primary PE was uncommon in this cohort and was increased by current though not past use of postmenopausal hormones or OCs, consistent irrespective of cigarette-smoking status. Expand
Differential association of oral and transdermal oestrogen-replacement therapy with venous thromboembolism risk
TLDR
Oral but not transdermal ERT is associated with risk of VTE in postmenopausal women, and data suggest that transder mal ERT might be safer than oral ERT with respect to thrombotic risk. Expand
Estrogen plus progestin and risk of venous thrombosis.
TLDR
Estrogen plus progestin therapy was associated with doubling the risk of venous thrombosis and the risks associated with age, overweight or obesity, and factor V Leiden were increased. Expand
Effects of oral and transdermal estrogen/progesterone regimens on blood coagulation and fibrinolysis in postmenopausal women. A randomized controlled trial.
TLDR
Oral estrogen/progesterone replacement therapy may result in coagulation activation and increased fibrinolytic potential, whereas opposed transdermal estrogen appears without any substantial effects on hemostasis. Expand
Increased risk of recurrent venous thromboembolism during hormone replacement therapy--results of the randomized, double-blind, placebo-controlled estrogen in venous thromboembolism trial (EVTET).
TLDR
The data strongly suggests that women who have previously suffered a VTE have an increased risk of recurrence on HRT, and this treatment should therefore be avoided in this patient group if possible. Expand
Risk of hospital admission for idiopathic venous thromboembolism among users of postmenopausal oestrogens
TLDR
The risk of idiopathic VTE is about three times higher among current users of replacement oestrogens than among non-users, however, the absolute risk is low for both groups and accounts for only a modest increase in morbidity. Expand
...
1
2
3
4
5
...